Can a propensity score matching method be applied to assessing efficacy from single-arm proof-of-concept trials in oncology?

Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression

Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response.

Estimating Smoking Cessation Rates and Smoking Prevalences Using Public Data and a Published Dynamic Model.

Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab.

Incorporating lesion-to-lesion heterogeneity into early oncology decision making.

Hallmarks of neurodegenerative disease: A systems pharmacology perspective.